Hemoglobin Glycation Index May Enhance Diagnosis of Prediabetes, Diabetes
Hemoglobin glycation index quantifies the magnitude and direction of interindividual variations in HbA1c that can be attributed to factors other than blood glucose levels.
Prediabetes
Prediabetes Prevalent in One-Quarter of Young Adults in the United States
In the United States, prediabetes occurs in about 1 in 5 adolescents and 1 in 4 young adults.
Increased Engagement of Primary Care Physicians Needed in Prediabetes Care
There are considerable gaps in primary care physician (PCP) knowledge regarding risk factors that prompt screening for prediabetes and management recommendations for patients with prediabetes.
Food Insecurity May Increase Risk for Prediabetes in US Adolescents
Researchers explored the association between food insecurity and the risk for obesity and prediabetes in adolescents and young adults.
Few Patients With Undiagnosed Prediabetes Informed by Providers About Risk
Few patients with undiagnosed prediabetes are told that they are at high risk for diabetes.
Preventing Progression to ASCVD and T2D: An Endocrine Society Guideline
The Endocrine Society published a clinical practice guideline cosponsored by the American Diabetes Association and the European Society of Endocrinology regarding the primary prevention of ASCVD and T2D.
Vitamin D Supplementation Beneficial for Glucose Metabolism
Vitamin D3 supplementation can improve glucose metabolism in patients at high risk of diabetes or with newly-diagnosed diabetes.
Tracking Prediabetes in Older Adults: Progression, Reversion, and Mortality
A majority of older adults with prediabetes remain stable or revert to normoglycemia over the long term.
How Does Sleep Duration Affect Glycemic Control in Diabetes?
Self-reported short and long sleep are both associated with adverse measures of glycemia among adults with prediabetes.
Metformin May Support Long-Term Weight Loss in Patients With Prediabetes, Obesity
Researchers found that 28.5, 62.6, and 13.4 percent of participants in the metformin, ILS, and placebo groups, respectively, had lost at least 5 percent of their weight after one year.
